Account
Inquiry
Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research. This compound demonstrates superior efficacy in glucose control and weight management compared to selective GLP-1 receptor agonists.
Our research-grade Tirzepatide features complete removal of trifluoroacetic acid (TFA) for enhanced safety. The white powder formulation maintains stability when properly stored and offers consistent performance in laboratory settings.
Key pharmacological benefits include: slowing gastric emptying, reducing hepatic glucose production, stimulating insulin secretion during hyperglycemia, and decreasing appetite. These mechanisms contribute to its potential in metabolic disorder research.
Manufacturing capabilities include mass production with customization options for vial size, content concentration, and packaging. Fresh production batches are available every 6-8 days to ensure optimal stability and performance.
For research purposes only. Not for human consumption. Proper storage at -20°C is recommended for long-term preservation of the lyophilized powder.
